Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 3
1982 1
1983 6
1984 3
1985 1
1986 6
1987 14
1988 12
1989 10
1990 13
1991 21
1992 11
1993 13
1994 7
1995 9
1996 8
1997 16
1998 14
1999 6
2000 4
2001 13
2002 6
2003 8
2004 6
2005 15
2006 12
2007 8
2008 9
2009 5
2010 8
2011 6
2012 6
2013 4
2014 9
2015 4
2016 7
2017 7
2018 6
2019 8
2020 5
2021 6
2022 6
2023 11
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

329 results

Results by year

Filters applied: . Clear all
Page 1
Nilutamide.
[No authors listed] [No authors listed] 2023 Mar 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2023 Mar 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643487 Free Books & Documents. Review.
Nilutamide is a first generation, oral nonsteroidal antiandrogen similar in structure to flutamide that is used in the therapy of prostate cancer. Nilutamide is associated with a low rate of serum aminotransferase elevations during therapy and with rare instances of …
Nilutamide is a first generation, oral nonsteroidal antiandrogen similar in structure to flutamide that is used in the therapy of pro …
Nilutamide: an antiandrogen for the treatment of prostate cancer.
Dole EJ, Holdsworth MT. Dole EJ, et al. Ann Pharmacother. 1997 Jan;31(1):65-75. doi: 10.1177/106002809703100112. Ann Pharmacother. 1997. PMID: 8997470 Review.
DATA SOURCES: MEDLINE (1980-1995) and CANCERLIT (1991-1995) were searched for English-language publications using the terms nilutamide, bicalutamide, and flutamide alone, and either nilutamide or androgen antagonists in combination with prostatic neoplasms. ...No co …
DATA SOURCES: MEDLINE (1980-1995) and CANCERLIT (1991-1995) were searched for English-language publications using the terms nilutamide …
Nilutamide.
Trasi NS, Fanwick PE, Taylor LS. Trasi NS, et al. Acta Crystallogr Sect E Struct Rep Online. 2012 Mar 1;68(Pt 3):o591. doi: 10.1107/S1600536812003728. Epub 2012 Feb 4. Acta Crystallogr Sect E Struct Rep Online. 2012. PMID: 22412506 Free PMC article.
THE CRYSTAL STRUCTURE OF NILUTAMIDE [SYSTEMATIC NAME: 5,5-dimethyl-3-[4-nitro-3-(trifluoro-meth-yl)phen-yl]imidazolidine-2,4-dione], C(12)H(10)F(3)N(3)O(4), was determined at 150 K. ...
THE CRYSTAL STRUCTURE OF NILUTAMIDE [SYSTEMATIC NAME: 5,5-dimethyl-3-[4-nitro-3-(trifluoro-meth-yl)phen-yl]imidazolidine-2,4-dione], …
Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.
Harris MG, Coleman SG, Faulds D, Chrisp P. Harris MG, et al. Drugs Aging. 1993 Jan-Feb;3(1):9-25. doi: 10.2165/00002512-199303010-00002. Drugs Aging. 1993. PMID: 8453188 Review.
Nilutamide is a nonsteroidal antiandrogen with affinity for androgen receptors but not for progestogen, estrogen, or glucocorticoid receptors. ...Nilutamide has a long half-life which permits once-daily administration. ...
Nilutamide is a nonsteroidal antiandrogen with affinity for androgen receptors but not for progestogen, estrogen, or glucocorticoid r …
Nilutamide-induced neutropenia.
Eaton VS, Blackmore TK. Eaton VS, et al. BJU Int. 2001 Nov;88(7):801-2. doi: 10.1046/j.1464-4096.2001.00905.x. BJU Int. 2001. PMID: 11890258 No abstract available.
Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review.
Du Plessis DJ. Du Plessis DJ. Urology. 1991;37(2 Suppl):20-4. doi: 10.1016/0090-4295(91)80097-q. Urology. 1991. PMID: 1992599 Review.
In a short-term (29 days) comparison of nilutamide plus buserelin and buserelin plus placebo, nilutamide (300 mg/day), significantly reduced bone pain, and fewer patients experienced worsening pain than in the control group. ...Nilutamide was generally well t …
In a short-term (29 days) comparison of nilutamide plus buserelin and buserelin plus placebo, nilutamide (300 mg/day), signifi …
Pharmacokinetics and metabolism of nilutamide.
Creaven PJ, Pendyala L, Tremblay D. Creaven PJ, et al. Urology. 1991;37(2 Suppl):13-9. doi: 10.1016/0090-4295(91)80096-p. Urology. 1991. PMID: 1992598 Review.
Studies using 14Carbon-nilutamide, radioimmunoassay, and high-performance liquid chromatography (HPLC) are reviewed. ...Steady-state plasma levels of nilutamide were reached in about two weeks. It can be concluded that in humans, unlike other species, plasma decay o …
Studies using 14Carbon-nilutamide, radioimmunoassay, and high-performance liquid chromatography (HPLC) are reviewed. ...Steady-state …
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Sweeney CJ, et al. Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3. Lancet Oncol. 2023. PMID: 36990608 Clinical Trial.
Participants were randomly assigned (1:1), using a centralised web-based system and stratified by volume of disease, planned use of concurrent docetaxel and bone antiresorptive therapy, comorbidities, and study site, to receive testosterone suppression plus oral enzalutamide (160 …
Participants were randomly assigned (1:1), using a centralised web-based system and stratified by volume of disease, planned use of concurre …
Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
Kassouf W, Tanguay S, Aprikian AG. Kassouf W, et al. J Urol. 2003 May;169(5):1742-4. doi: 10.1097/01.ju.0000057795.97626.66. J Urol. 2003. PMID: 12686822
During followup 6 of the 28 patients died 1 of whom was a nilutamide responder. No patient died while on nilutamide. CONCLUSIONS: Nilutamide can achieve a significant sustained PSA response with a favorable toxicity profile. Patients with a previous antiandro …
During followup 6 of the 28 patients died 1 of whom was a nilutamide responder. No patient died while on nilutamide. CONCLUSIO …
Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats and in human liver microsomes.
Horsmans Y, Lannes D, Larrey D, Tinel M, Letteron P, Loeper J, Pessayre D. Horsmans Y, et al. Xenobiotica. 1991 Dec;21(12):1559-70. doi: 10.3109/00498259109044405. Xenobiotica. 1991. PMID: 1785203
Nilutamide (100 microM) markedly inhibited mephenytoin 4-hydroxylase activity in human liver microsomes. ...It is suggested that inhibition is likely to occur in vivo in humans receiving therapeutic doses of nilutamide....
Nilutamide (100 microM) markedly inhibited mephenytoin 4-hydroxylase activity in human liver microsomes. ...It is suggested that inhi …
329 results